|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGFBP5 |
Gene summary for IGFBP5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGFBP5 | Gene ID | 3488 |
| Gene name | insulin like growth factor binding protein 5 | |
| Gene Alias | IBP5 | |
| Cytomap | 2q35 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R433 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3488 | IGFBP5 | GSM4909281 | Human | Breast | IDC | 4.03e-15 | 5.31e-01 | 0.21 |
| 3488 | IGFBP5 | GSM4909285 | Human | Breast | IDC | 5.28e-97 | 1.57e+00 | 0.21 |
| 3488 | IGFBP5 | GSM4909293 | Human | Breast | IDC | 4.05e-142 | 2.25e+00 | 0.1581 |
| 3488 | IGFBP5 | GSM4909295 | Human | Breast | IDC | 3.24e-13 | 8.65e-01 | 0.0898 |
| 3488 | IGFBP5 | GSM4909296 | Human | Breast | IDC | 4.37e-38 | 1.22e+00 | 0.1524 |
| 3488 | IGFBP5 | GSM4909301 | Human | Breast | IDC | 6.15e-213 | 2.52e+00 | 0.1577 |
| 3488 | IGFBP5 | GSM4909311 | Human | Breast | IDC | 8.85e-22 | 7.88e-01 | 0.1534 |
| 3488 | IGFBP5 | GSM4909312 | Human | Breast | IDC | 1.17e-132 | 2.00e+00 | 0.1552 |
| 3488 | IGFBP5 | GSM4909313 | Human | Breast | IDC | 3.91e-54 | 1.74e+00 | 0.0391 |
| 3488 | IGFBP5 | GSM4909315 | Human | Breast | IDC | 5.13e-32 | 1.04e+00 | 0.21 |
| 3488 | IGFBP5 | GSM4909317 | Human | Breast | IDC | 1.73e-18 | 6.94e-01 | 0.1355 |
| 3488 | IGFBP5 | GSM4909319 | Human | Breast | IDC | 6.63e-84 | 1.81e+00 | 0.1563 |
| 3488 | IGFBP5 | GSM4909320 | Human | Breast | IDC | 1.43e-05 | 6.00e-01 | 0.1575 |
| 3488 | IGFBP5 | GSM4909321 | Human | Breast | IDC | 3.42e-08 | 5.51e-01 | 0.1559 |
| 3488 | IGFBP5 | M5 | Human | Breast | IDC | 2.90e-19 | 1.32e+00 | 0.1598 |
| 3488 | IGFBP5 | DCIS2 | Human | Breast | DCIS | 1.35e-05 | 1.69e-01 | 0.0085 |
| 3488 | IGFBP5 | CA_HPV_3 | Human | Cervix | CC | 5.04e-19 | 5.55e-01 | 0.0414 |
| 3488 | IGFBP5 | N_HPV_2 | Human | Cervix | N_HPV | 2.52e-04 | 3.22e-01 | -0.0131 |
| 3488 | IGFBP5 | AEH-subject1 | Human | Endometrium | AEH | 6.71e-21 | -8.05e-01 | -0.3059 |
| 3488 | IGFBP5 | AEH-subject2 | Human | Endometrium | AEH | 4.59e-19 | -7.97e-01 | -0.2525 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:00459266 | Oral cavity | OSCC | negative regulation of growth | 135/7305 | 249/18723 | 7.29e-07 | 1.03e-05 | 135 |
| GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
| GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
| GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
| GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
| GO:00303238 | Oral cavity | OSCC | respiratory tube development | 95/7305 | 181/18723 | 1.53e-04 | 1.07e-03 | 95 |
| GO:00303248 | Oral cavity | OSCC | lung development | 91/7305 | 177/18723 | 5.18e-04 | 3.01e-03 | 91 |
| GO:00075657 | Oral cavity | OSCC | female pregnancy | 98/7305 | 193/18723 | 5.66e-04 | 3.27e-03 | 98 |
| GO:004259316 | Oral cavity | OSCC | glucose homeostasis | 125/7305 | 258/18723 | 1.21e-03 | 6.08e-03 | 125 |
| GO:003350016 | Oral cavity | OSCC | carbohydrate homeostasis | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
| GO:00605416 | Oral cavity | OSCC | respiratory system development | 100/7305 | 203/18723 | 1.83e-03 | 8.60e-03 | 100 |
| GO:002261214 | Oral cavity | OSCC | gland morphogenesis | 62/7305 | 118/18723 | 1.91e-03 | 8.94e-03 | 62 |
| GO:00342495 | Oral cavity | OSCC | negative regulation of cellular amide metabolic process | 130/7305 | 273/18723 | 2.20e-03 | 1.00e-02 | 130 |
| GO:00434916 | Oral cavity | OSCC | protein kinase B signaling | 103/7305 | 211/18723 | 2.29e-03 | 1.02e-02 | 103 |
| GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
| GO:003087910 | Oral cavity | OSCC | mammary gland development | 69/7305 | 137/18723 | 4.43e-03 | 1.79e-02 | 69 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGFBP5 | SNV | Missense_Mutation | novel | c.388N>A | p.Glu130Lys | p.E130K | P24593 | protein_coding | tolerated(0.46) | benign(0.109) | TCGA-OL-A5DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IGFBP5 | SNV | Missense_Mutation | novel | c.337G>C | p.Glu113Gln | p.E113Q | P24593 | protein_coding | tolerated(0.4) | benign(0.29) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| IGFBP5 | SNV | Missense_Mutation | novel | c.503G>A | p.Gly168Glu | p.G168E | P24593 | protein_coding | tolerated(0.52) | benign(0.031) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IGFBP5 | SNV | Missense_Mutation | novel | c.319N>T | p.Arg107Cys | p.R107C | P24593 | protein_coding | deleterious(0) | benign(0.001) | TCGA-AG-3575-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IGFBP5 | SNV | Missense_Mutation | novel | c.724N>G | p.Trp242Gly | p.W242G | P24593 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IGFBP5 | SNV | Missense_Mutation | novel | c.577C>T | p.Arg193Cys | p.R193C | P24593 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IGFBP5 | SNV | Missense_Mutation | rs780625278 | c.661N>T | p.Arg221Cys | p.R221C | P24593 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IGFBP5 | SNV | Missense_Mutation | c.538N>T | p.Ala180Ser | p.A180S | P24593 | protein_coding | tolerated(0.86) | benign(0.021) | TCGA-BS-A0VI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| IGFBP5 | SNV | Missense_Mutation | rs763073487 | c.526C>T | p.Arg176Trp | p.R176W | P24593 | protein_coding | tolerated(0.06) | possibly_damaging(0.551) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IGFBP5 | SNV | Missense_Mutation | c.603G>T | p.Gln201His | p.Q201H | P24593 | protein_coding | tolerated(0.07) | possibly_damaging(0.683) | TCGA-D1-A174-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3488 | IGFBP5 | DRUGGABLE GENOME | TGFBETA1 | 16214131 | ||
| 3488 | IGFBP5 | DRUGGABLE GENOME | DHT | ANDROSTANOLONE | 16368782 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |